Bempedoic acid - Esperion Therapeutics
Alternative Names: ESP-55016; ETC-1002; NEXLETOL; NILEMDO; NilemdoLatest Information Update: 27 Aug 2024
At a glance
- Originator Esperion Therapeutics
- Developer Daiichi Sankyo Europe; Esperion Therapeutics; Otsuka Pharmaceutical
- Class Antihyperlipidaemics; Antihypertensives; Dicarboxylic acids; Fatty acids; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants; ATP citrate (pro S) lyase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Dyslipidaemias; Hypercholesterolaemia
- Registered Cardiovascular disorders
- Phase I Hypertension
Most Recent Events
- 12 Aug 2024 Esperion plans New Drug Applications for Hypercholesterolemia in Canada, Australia and Israel by the end of 2024
- 12 Aug 2024 Otsuka plans to file a NDA for Hypercholesterolemia in Japan in the second half of 2024
- 29 May 2024 Adverse events and efficacy data from the phase-III CLEAR Outcomes trial in Cardiovascular disorders released by Daiichi Sankyo Company